Companies in the News

Encoded Therapeutics Announces $135 Million Series D Financing to Support First Clinical Trials in S

Financing led by GV with participation from Matrix Capital Management, ARCH Venture Partners, Illumina Ventures, RTW Investments, Boxer Capital, Nolan Capital, HBM Genomics, Menlo Ventures, Meritech Capital, Farallon Capital Management, and Softbank Vision Fund 2 ETX101, Encoded’s lead asset, was granted Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation by FDA for the treatment of SCN1A+ Dravet Syndrome Encoded plans to initiate ENVISION, an observational study in SCN1A+ Dravet Syndrome, in the second half of 2020 and Phase I clinical trials of ETX101 in 2021 SOUTH SAN FRANCISCO, Calif. – July 22, 2020 – Encoded Therapeutics, Inc. (Encoded), a precision gene therapy compan